Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0135 | 0.1312 | 0.1944 |
Echinococcus granulosus | Smad4 | 0.0026 | 0.0025 | 0.0084 |
Echinococcus granulosus | TGF beta signal transducer SmadC | 0.0026 | 0.0025 | 0.0084 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0277 | 0.2976 | 1 |
Schistosoma mansoni | smad1 5 8 and | 0.0026 | 0.0025 | 0.0037 |
Schistosoma mansoni | hypothetical protein | 0.0277 | 0.2976 | 0.441 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0277 | 0.2976 | 0.2959 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0052 | 0.0338 | 0.5 |
Schistosoma mansoni | smad | 0.0026 | 0.0025 | 0.0037 |
Loa Loa (eye worm) | RNA binding protein | 0.0135 | 0.1312 | 0.129 |
Loa Loa (eye worm) | hypothetical protein | 0.0277 | 0.2976 | 0.2959 |
Schistosoma mansoni | hypothetical protein | 0.0598 | 0.6749 | 1 |
Echinococcus multilocularis | Smad4 | 0.0026 | 0.0025 | 0.0084 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0375 | 0.4127 | 0.4112 |
Brugia malayi | RNA binding protein | 0.0135 | 0.1312 | 0.129 |
Schistosoma mansoni | tar DNA-binding protein | 0.0135 | 0.1312 | 0.1944 |
Echinococcus multilocularis | mothers against decapentaplegic 5 | 0.0026 | 0.0025 | 0.0084 |
Brugia malayi | hypothetical protein | 0.0052 | 0.0338 | 0.0314 |
Brugia malayi | N-terminal motif family protein | 0.0371 | 0.4084 | 0.407 |
Loa Loa (eye worm) | TAR-binding protein | 0.0135 | 0.1312 | 0.129 |
Echinococcus granulosus | GPCR family 2 | 0.0277 | 0.2976 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0135 | 0.1312 | 0.4408 |
Schistosoma mansoni | smad1 5 8 and | 0.0026 | 0.0025 | 0.0037 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0052 | 0.0338 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0052 | 0.0338 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0135 | 0.1312 | 0.1944 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0052 | 0.0338 | 0.5 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0277 | 0.2976 | 1 |
Brugia malayi | hypothetical protein | 0.0034 | 0.0121 | 0.0096 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.0338 | 0.0314 |
Onchocerca volvulus | Rap guanine nucleotide exchange factor 1 homolog | 0.0371 | 0.4084 | 0.5 |
Schistosoma mansoni | TGF-beta signal transducer Smad2 | 0.0026 | 0.0025 | 0.0037 |
Leishmania major | hypothetical protein, conserved | 0.0052 | 0.0338 | 0.5 |
Schistosoma mansoni | smad1 5 8 and | 0.0026 | 0.0025 | 0.0037 |
Echinococcus multilocularis | TGF beta signal transducer SmadC | 0.0026 | 0.0025 | 0.0084 |
Brugia malayi | MH2 domain containing protein | 0.0375 | 0.4127 | 0.4112 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0135 | 0.1312 | 0.129 |
Schistosoma mansoni | tar DNA-binding protein | 0.0135 | 0.1312 | 0.1944 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0135 | 0.1312 | 0.129 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0598 | 0.6749 | 0.6741 |
Schistosoma mansoni | hypothetical protein | 0.0277 | 0.2976 | 0.441 |
Schistosoma mansoni | hypothetical protein | 0.0277 | 0.2976 | 0.441 |
Loa Loa (eye worm) | hypothetical protein | 0.0598 | 0.6749 | 0.6741 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0277 | 0.2976 | 1 |
Echinococcus multilocularis | GPCR, family 2 | 0.0277 | 0.2976 | 1 |
Echinococcus granulosus | mothers against decapentaplegic 5 | 0.0026 | 0.0025 | 0.0084 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0277 | 0.2976 | 0.2959 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0375 | 0.4127 | 0.4112 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0052 | 0.0338 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0135 | 0.1312 | 0.4408 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0052 | 0.0338 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0371 | 0.4084 | 0.407 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0277 | 0.2976 | 1 |
Schistosoma mansoni | Smad4 | 0.0026 | 0.0025 | 0.0037 |
Echinococcus multilocularis | smad | 0.0026 | 0.0025 | 0.0084 |
Schistosoma mansoni | tar DNA-binding protein | 0.0135 | 0.1312 | 0.1944 |
Echinococcus granulosus | smad | 0.0026 | 0.0025 | 0.0084 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0052 | 0.0338 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0277 | 0.2976 | 0.441 |
Brugia malayi | TAR-binding protein | 0.0135 | 0.1312 | 0.129 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0277 | 0.2976 | 0.2959 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.8184 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.